Yifan Pharmaceutical Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Xian Feng Cheng

Chief executive officer

CN¥624.0k

Total compensation

CEO salary percentage	n/a
CEO tenure	9.6yrs
CEO ownership	40.8%
Management average tenure	2yrs
Board average tenure	8.8yrs

Recent management updates

Recent updates

Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Shares Leap 28% Yet They're Still Not Telling The Full Story

May 08

A Piece Of The Puzzle Missing From Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price

Mar 01

CEO

Xian Feng Cheng (55 yo)

9.6yrs

Tenure

CN¥624,000

Compensation

Mr. Xian feng Cheng serves as the Chairman of the Board of Directors and General Manager at Yifan Pharmaceutical Co., Ltd.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Xian Feng Cheng	Chairman of the Board of Directors & GM	no data	CN¥624.00k	40.82% CN¥ 6.9b
Hai Xia Yu	Chief Financial Officer	11.5yrs	CN¥504.00k	0.056% CN¥ 9.5m
Xing Lin	Deputy GM & Director	no data	CN¥564.00k	0.063% CN¥ 10.6m
Deqi Feng	Board Secretary	no data	CN¥480.00k	0.60% CN¥ 101.4m
William Tan	Director of Sales Team	no data	no data	no data
Ximing Li	Deputy General Manager	2yrs	no data	0.0020% CN¥ 338.6k
Yuhong Geng	Deputy General Manager	2yrs	no data	0.0032% CN¥ 540.8k
Lian Chun Zhang	Member of the Supervisory Board	no data	CN¥234.20k	no data
Dawei Zhang	Financial Controller	no data	no data	0.0032% CN¥ 534.1k

2.0yrs

Average Tenure

47yo

Average Age

Experienced Management: 002019's management team is considered experienced (2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Xian Feng Cheng	Chairman of the Board of Directors & GM	9.6yrs	CN¥624.00k	40.82% CN¥ 6.9b
Xing Lin	Deputy GM & Director	11.5yrs	CN¥564.00k	0.063% CN¥ 10.6m
Deqi Feng	Board Secretary	8.1yrs	CN¥480.00k	0.60% CN¥ 101.4m
Lian Chun Zhang	Member of the Supervisory Board	9.6yrs	CN¥234.20k	no data
Jun Wang	Supervisor	6.2yrs	no data	0.000010% CN¥ 1.7k
Yi Qun Ye	Director	9.6yrs	CN¥480.00k	0.058% CN¥ 9.8m
Ben Yu Zhou	Director	9.6yrs	CN¥480.00k	0.032% CN¥ 5.4m
Hongquan Liu	Independent Director	3.5yrs	no data	no data
Xintu Lei	Independent Director	5.1yrs	CN¥100.00k	no data
Hong Cheng Gen	Independent Director	5.1yrs	CN¥100.00k	no data

8.8yrs

Average Tenure

50.5yo

Average Age

Experienced Board: 002019's board of directors are considered experienced (8.8 years average tenure).

Yifan Pharmaceutical Management

Management criteria checks 3/4

Key information

Recent management updates

Yifan Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Less than half of directors are independent

Less than half of directors are independent

Yifan Pharmaceutical Co., Ltd., Annual General Meeting, May 06, 2022

Recent updates

Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Shares Leap 28% Yet They're Still Not Telling The Full Story

Yifan Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Yifan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

A Piece Of The Puzzle Missing From Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price

Price target decreased by 11% to CN¥17.83

Yifan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.03 (vs CN¥0.032 in 3Q 2022)

New minor risk - Earnings quality

Yifan Pharmaceutical Co., Ltd. (SZSE:002019) announces an Equity Buyback for CNY 50 million worth of its shares.

Second quarter 2023 earnings released: EPS: CN¥0.039 (vs CN¥0.031 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.23 in FY 2021)

Price target decreased to CN¥16.42

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.032 (vs CN¥0.069 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.031 (vs CN¥0.062 in 2Q 2021)

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Yifan Pharmaceutical Co., Ltd., Annual General Meeting, May 06, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2021 earnings released: EPS CN¥0.069 (vs CN¥0.16 in 3Q 2020)

Investor sentiment improved over the past week

Yifan Pharmaceutical Co., Ltd. (SZSE:002019) announces an Equity Buyback for CNY 150 million worth of its shares.

Second quarter 2021 earnings released: EPS CN¥0.062 (vs CN¥0.32 in 2Q 2020)

Yifan Pharmaceutical Co., Ltd. Announces to Implement Final Cash Distribution Plan A Shares for 2020, Payable on 17 May 2021

First quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.26 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.80 (vs CN¥0.75 in FY 2019)

Investor sentiment deteriorated over the past week

Yifan Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

Investor sentiment improved over the past week

New 90-day low: CN¥16.91

New 90-day low: CN¥18.19

New 90-day low: CN¥20.47

New 90-day low: CN¥22.10

Third quarter earnings released

New 90-day low: CN¥23.93

First half earnings released

Yifan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 31, 2020

New 90-day high - CN¥32.91

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age